---
document_datetime: 2025-07-08 14:58:47
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cibinqo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cibinqo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.1021358
conversion_datetime: 2025-12-25 08:32:37.447114
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cibinqo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                 |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10976 /202409  | Periodic Safety Update EU Single assessment - abrocitinib                                      | 25/04/2025                          | 23/06/2025                                  | SmPC and PL                      | Please refer to Cibinqo- EMEA/H/C/PSUSA/00010976/202409 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0021              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 29/10/2024                          | 23/06/2025                                  | SmPC                             |                                                                                                                                                                         |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0020             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/10/2024   | n/a        |             |                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------|
| PSUSA/10976 /202403 | Periodic Safety Update EU Single assessment - abrocitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/10/2024   | n/a        |             | PRAC Recommendation - maintenance                                        |
| IB/0018             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/08/2024   | 23/06/2025 | SmPC        |                                                                          |
| PSUSA/10976 /202309 | Periodic Safety Update EU Single assessment - abrocitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/04/2024   | n/a        |             | PRAC Recommendation - maintenance                                        |
| IA/0016             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 05/04/2024   | n/a        |             |                                                                          |
| II/0010             | Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis for CIBINQO based on final results from non-clinical study 00655292 [21GR211] and interim results from clinical study B7451015; this is a Phase III multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medicines, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is | 22/02/2024   | 21/03/2024 | SmPC and PL | Please refer to Scientific Discussion 'Cibinqo-H-C-005452- II-Var.0010'. |

<div style=\"page-break-after: always\"></div>

|           | line with the latest QRD template version 10.3. The RMP (version 4.4) is acceptable. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                   |            |            |                 | brought in   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------|
| IAIN/0015 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/02/2024 | 21/03/2024 | Annex II and PL |              |
| IA/0013/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 05/10/2023 | n/a        |                 |              |
| IA/0012   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                 | 05/10/2023 | n/a        |                 |              |

<div style=\"page-break-after: always\"></div>

| PSUSA/10976 /202303   | Periodic Safety Update EU Single assessment - abrocitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/09/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                          |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------|
| IB/0011               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/06/2023   | 25/01/2024 | SmPC                  |                                                                                            |
| PSUSA/10976 /202209   | Periodic Safety Update EU Single assessment - abrocitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/04/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                          |
| IA/0008               | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/04/2023   | n/a        |                       |                                                                                            |
| A20/0003              | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 28 January 2022 the opinion of the European Medicines Agency further to the safety issues on MACE, VTE, serious infections, malignancy and mortality for all JAK inhibitors used in the treatment of inflammatory disorders. The CHMP was requested to assess the impact thereof on the benefit-risk balance of Cibinqo, Jyseleca, Olumiant, Rinvoq and Xeljanz and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion was adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. | 23/01/2023   | 10/03/2023 | SmPC, Annex II and PL | Please refer to the assessment report: Cibinqo (abrocitinib) EMEA/H-A20/1517/C/005452/0003 |

<div style=\"page-break-after: always\"></div>

| II/0007             | To update section 5.1 of the SmPC in order to update long-term efficacy data based on the results from studies B7451012, B7451013, B7451015 and B7451029. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                       | 16/02/2023   | 25/01/2024   | SmPC   | SmPC section 5.1 has been revised to update the long-term efficacy data. Efficacy data through Week 96 of cumulative treatment demonstrated that most initial responders maintained their response through Week 96. The response to abrocitinib treatment decreased slightly over time through Week 48 among subjects who achieved initial response at Week 12. However, there was no clinically meaningful decrease in IGA, EASI-75, or PP-NRS4 response rate between Week 48 and Week 96. Efficacy data through 96 weeks of cumulative treatment continue to support the long-term efficacy of both abrocitinib 100 mg QD and 200 mg QD in the treatment of adult patients with moderate-to- severe AD. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10976 /202203 | Periodic Safety Update EU Single assessment - abrocitinib                                                                                                                                                                                                                                                                                                                                                                                         | 29/09/2022   | n/a          |        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0005             | Update of section 4.5 of the SmPC based on final results from Drug-Drug Interaction (DDI) study B7451092. This is a Phase I, open-label, fixed- sequence, 2-period study to estimate the effect of multiple dose abrocitinib on the pharmacokinetics of single doses of caffeine, efavirenz, and omeprazole in healthy participants. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 08/09/2022   | 10/03/2023   | SmPC   | The effect of abrocitinib on CYP1A2, 2B6, and 2C19 enzymes was assessed in vivo. Abrocitinib is a moderate inhibitor of CYP2C19 enzyme; caution should thus be exercised when using abrocitinib concomitantly with narrow therapeutic index medicines that are primarily metabolised by CYP2C19. Further, abrocitinib is also a mild inhibitor of CYP1A2 enzyme, nevertheless no general dose adjustment can be recommended. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0001   | Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015.The RMP version v1.0 has also been submitted. In addition, MAH took the opportunity to implement editorial changes in the SmPC and to update the contact details of the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                 | 01/09/2022   | 10/03/2023   | SmPC and PL   | Based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015, SmPC sections 4.4 and 4.8 of the SmPC were updated. It was highlighted in SmPC section 4.4 that tuberculosis was observed in clinical studies with abrocitinib; and in SmPC sections 4.4 and 4.8 that the rate of herpes zoster infections was higher in patients who were treated with 200 mg, with a medical history of herpes zoster, with a confirmed ALC < 1 Ã— 103/mm3 prior to the event. For more information, please refer to the Summary of Product Characteristics.                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002   | Update of sections 4.2 and 4.5 of the SmPC based on results from Drug-Drug Interaction (DDI) study B7451061; A phase 1, randomised, crossover study to evaluate relative bioavailability of abrocitinib oral suspension and effect of an acid-reducing agent on the bioavailability of abrocitinib commercial tablet and to assess the taste of abrocitinib oral formulations in healthy adult participants aged 18 to 55 years of age. The Package Leaflet is updated in accordance. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 07/07/2022   | 10/03/2023   | SmPC          | When abrocitinib 200 mg was administered concomitantly with famotidine 40 mg, an H2-receptor antagonist, abrocitinib active moiety exposures decreased by approximately 35%. The effect of elevating gastric pH with antacids, or proton pump inhibitors (omeprazole) on the pharmacokinetics of abrocitinib has not been studied and may be similar to that seen with famotidine. Therefore, the higher 200 mg daily dose should be considered for patients treated concomitantly with products which increase gastric pH, as they may reduce the efficacy of abrocitinib. For more information, please refer to the Summary of Product Characteristics. |